New Teva ad campaign focuses on patients struggling with psychiatric drug side effect

Te­va is fo­cused on grow­ing its Auste­do brand to treat tar­dive dysk­i­ne­sia, a side ef­fect of some men­tal health med­ica­tions, jump­start­ing this year with a new jin­gle and cam­paign dri­ving pa­tient aware­ness.

A video ad­ver­tise­ment, de­buted last month, fea­tures an ac­tress strug­gling to pour a cup of cof­fee. Tar­dive dysk­i­ne­sia, or TD, can cause in­vol­un­tary move­ments, mak­ing sim­ple dai­ly tasks chal­leng­ing. Auste­do was first ap­proved to treat TD in 2017, then again last year as an ex­tend­ed-re­lease once-dai­ly tablet.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Shorter TB Regimen Misses the Mark

Shorter high-dose rifampicin regimens proved safe for treating pulmonary tuberculosis (TB), but failed to demonstrate noninferiority compared with the standard 6-month regimen, a phase III

Read More »